This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koshiyama, H. Articles by Minamikawa, J. Search for Related Content PubMed PubMed Citation Articles by Koshiyama, H. Articles by Minamikawa, J.

Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes¹

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Hyogo 660-0828, Japan

Address all correspondence and requests for reprints to: Dr. H. Koshiyama, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo 660-0828, Japan.

It has been suggested that bisphosphonates may have some antiatherogenic actions in experimental animals or in vitro, but their effects on the atherogenic process in humans has not been reported. In the present study the effect of etidronate treatment on carotid arterial intima-media thickness was prospectively examined in 57 subjects with type 2 diabetes associated with osteopenia. After 1 yr of therapy with cyclical etidronate (200 mg/day for 2 weeks every 3 months), intima-media thickness showed a decrease (mean ± SE, -0.038 ± 0.011 mm), which was significantly different from a change in 57 control subjects (0.023 ± 0.015 mm; P < 0.005). Cardiovascular parameters were not changed after etidronate treatment. These findings suggest that etidronate in clinical dosage may have an antiatherogenic action, at least in type 2 diabetes, although its mechanisms remain to be elucidated.

This article has been cited by other articles:

				T. Nagasaki, M. Inaba, S. Yamada, K. Shirakawa, Y. Nagata, Y. Kumeda, Y. Hiura, H. Tahara, E. Ishimura, and Y. Nishizawa Decrease of brachial-ankle pulse wave velocity in female subclinical hypothyroid patients during normalization of thyroid function: a double-blind, placebo-controlled study Eur. J. Endocrinol., March 1, 2009; 160(3): 409 - 415. [Abstract] [Full Text] [PDF]

				N. D. Toussaint, G. J. Elder, and P. G. Kerr Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 221 - 233. [Abstract] [Full Text] [PDF]

				M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297. [Abstract] [Full Text] [PDF]

				M Bevilacqua, L J Dominguez, S Rosini, and M Barbagallo Bisphosphonates and atherosclerosis: why? Lupus, September 1, 2005; 14(9): 773 - 779. [Abstract] [PDF]